Quantitative immunocytochemistry method to improve patient's response prediction
Company 2019
Navigate BioPharma Services, Inc., Carlsbad, USA(1)
The First Affiliated Hospital of Xiamen University, Fujian, China(2)
The University of Texas MD Anderson Cancer Center, Houston, USA(3)
The First Affiliated Hospital of Xiamen University, Fujian, China(2)
The University of Texas MD Anderson Cancer Center, Houston, USA(3)
Programmed cell death protein 1 (PD-1) is an immune checkpoint targeted by some anti-cancer treatments. Yet, the efficiency of the response can vary greatly and there is a need for biomarkers to better predict patient's response. In the present study, the researchers analyzed tumor tissue samples from 414 patients with B-cell lymphoma using quantitative immunocytochemistry 3 markers related to PD-1 in parallel with survival analysis of the patients. The results show the potential for quantitative immunocytochemistry for better patient's response prediction.
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consor
Christine A. Vaupel(1), Bing Xu(2), Ken H. Young(3)
Added on: 07-28-2021
[1] https://www.nature.com/articles/s41379-018-0193-5[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
